Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Mergers & Acquisitions
Alexion to acquire autoimmune drug firm Syntimmune for up to $1.2 billion
by Ryan Cross
September 29, 2018
| A version of this story appeared in
Volume 96, Issue 39
Alexion Pharmaceuticals will acquire the Boston-based biotech firm Syntimmune for $400 million plus up to $800 million in potential milestone payments. Syntimmune says its lead antibody drug candidate, SYNT001, has the potential to treat autoimmune disease by facilitating the destruction of human immunoglobulin G antibodies that cause the disease. SYNT001 is already undergoing testing in people with a rare autoimmune blistering disease called pemphigus and a rare form of autoimmune anemia.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter